Other Clinical Trial - Study of Dotatate Imaging in Breast Cancer

Status Active, not recruiting

Clinical Trial Summary

This will be a Phase 2 clinical trial to assess somatostatin receptor (SSTR) expression in Stage IV estrogen receptor positive (ER+) breast cancer using Gallium-68 DOTATATE or Copper-64 DOTATATE PET/CT.

Clinical Trial Description

Subjects with metastatic breast cancer are planned to be enrolled to undergo Gallium-68 DOTATATE or Copper-64 DOTATATE PET/CT imaging at one time point. SSTR uptake in metastatic lesions will be evaluated by independent central review (ICR). FDG PET and bone scans will also be performed within +/- 3 weeks of DOTATATE imaging. The primary objective of this study is to evaluate uptake of Gallium-68 DOTATATE or Copper-64 DOTATATE in metastatic ER+ breast cancer lesions. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05880394
Study type	Interventional
Source	Hoag Memorial Hospital Presbyterian
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	January 10, 2023
Completion date	July 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04469127` - A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients.	Phase 1/Phase 2
Withdrawn	`NCT03032614` - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients	Phase 2
Terminated	`NCT04123704` - Sitravatinib in Metastatic Breast Cancer	Phase 2
Recruiting	`NCT05377047` - Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer	N/A
Completed	`NCT03304210` - PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer	Phase 1
Completed	`NCT05054374` - A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer	Phase 1/Phase 2
Recruiting	`NCT05559528` - BRaziLian outcomE for metAStatic breasT Cancer
Active, not recruiting	`NCT05090358` - Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer	Phase 2
Recruiting	`NCT05033925` - Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients	Phase 1/Phase 2
Recruiting	`NCT03401359` - The Resistance and Immune Response to Palbociclib in Breast Cancer	N/A
Active, not recruiting	`NCT03870919` - Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients	N/A
Not yet recruiting	`NCT05860907` - Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis	Phase 4
Completed	`NCT00393341` - Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer	N/A
Recruiting	`NCT05625087` - Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib	Phase 2
Completed	`NCT04566458` - RWD Study in HER2+ mBC Patients in Third-Line Therapy
Recruiting	`NCT06075810` - A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer	Phase 1
Recruiting	`NCT04697043` - The Benefit of Surgery in Stage IV of Breast Cancer	N/A
Recruiting	`NCT05837533` - Multicenter Study to Evaluate a Systematized Communication Model for Breast Cancer Patients	N/A
Active, not recruiting	`NCT03324425` - Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer	Phase 2
Recruiting	`NCT05670054` - Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients	Phase 3